Recruiting
Phase 1
Phase 2

Precision Therapies

Sponsor:

Australian & New Zealand Children's Haematology/Oncology Group

Code:

NCT06208657

Conditions

Childhood Cancer

Childhood Solid Tumor

Childhood Brain Tumor

Recurrent Cancer

Refractory Cancer

Eligibility Criteria

Sex: All

Age: 0 - 21

Healthy Volunteers: Not accepted

Interventions

Paxalisib, Irinotecan, Temozolomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Australian & New Zealand Children's Haematology/Oncology Group on 2025-02-21.